%0 Journal Article
%A Calderón Parra, Jorge
%A Guisado Vasco, Pablo
%A Montejano Sánchez, Rocío
%A Estrada Pérez, Vicente
%A Cuevas Tascón, Guillermo
%A Aguareles Gorines, José
%A Arribas, José
%A Erro Iribarren, Marta
%A Calvo Salvador, Marina
%A Fernández Cruz, Ana
%A Ramos Martínez, Antonio
%A Muñez Rubio, Elena
%T Use of Monoclonal Antibodies in Immunocompromised Patients Hospitalized with Severe COVID-19: A Retrospective Multicenter Cohort
%D 2023
%@ 2077-0383
%U https://hdl.handle.net/20.500.14352/72323
%X Objective: We aim to describe the safety and efficacy of sotrovimab in severe cases of COVID-19 in immunocompromised hosts. Methods: We used a retrospective multicenter cohort including immunocompromised hospitalized patients with severe COVID-19 treated with sotrovimab between October 2021 and December 2021. Results: We included 32 patients. The main immunocompromising conditions were solid organ transplantation (46.9%) and hematological malignancy (37.5%). Seven patients (21.9%) had respiratory progression: 12.5% died and 9.4% required mechanical ventilation. Patients treated within the first 14 days of their symptoms had a lower progression rate: 12.0% vs. 57.1%, p = 0.029. No adverse event was attributed to sotrovimab. Conclusions: Sotrovimab was safe and may be effective in its use for immunocompromised patients with severe COVID-19. More studies are needed to confirm these preliminary data.
%~